Arvinas (NASDAQ:ARVN) Stock Price Up 7.4% – Time to Buy?

Arvinas, Inc. (NASDAQ:ARVN)’s share price traded up 7.4% during trading on Tuesday . The company traded as high as $19.75 and last traded at $19.67. 144,908 shares traded hands during trading, a decline of 84% from the average session volume of 886,925 shares. The stock had previously closed at $18.31.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ARVN shares. Guggenheim reissued a “buy” rating and set a $57.00 price objective on shares of Arvinas in a research note on Wednesday, February 12th. Stephens assumed coverage on shares of Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 price target for the company. BTIG Research started coverage on Arvinas in a research note on Tuesday, December 10th. They set a “buy” rating and a $69.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research note on Friday, February 7th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $82.00 price objective (down from $88.00) on shares of Arvinas in a research report on Wednesday, February 12th. Thirteen analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $60.00.

Arvinas Trading Down 0.9 %

The company has a market cap of $1.26 billion, a P/E ratio of -6.63 and a beta of 1.88. The business has a 50 day moving average price of $18.55 and a 200-day moving average price of $23.02.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the previous year, the company earned ($2.53) earnings per share. On average, sell-side analysts expect that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Institutional Trading of Arvinas

Several hedge funds and other institutional investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. bought a new stake in shares of Arvinas during the 4th quarter valued at approximately $28,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Arvinas by 0.7% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 433,531 shares of the company’s stock worth $8,311,000 after purchasing an additional 3,047 shares during the last quarter. Voloridge Investment Management LLC acquired a new position in shares of Arvinas in the fourth quarter valued at approximately $749,000. Woodline Partners LP raised its holdings in Arvinas by 39.2% in the 4th quarter. Woodline Partners LP now owns 692,733 shares of the company’s stock valued at $13,280,000 after buying an additional 194,996 shares during the last quarter. Finally, Twinbeech Capital LP acquired a new stake in Arvinas during the 4th quarter worth approximately $3,146,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.